摘要
目的观察曲妥珠单抗联合多西紫杉醇对Her-2/neu高表达的局部晚期乳腺癌新辅助化疗的疗效。方法 16例Her-2/neu高表达的局部晚期乳腺癌患者接受曲妥珠单抗联合多西紫杉醇的方案治疗。曲妥珠单抗的首次剂量为4mg/kg,以后剂量为2mg/kg,每7d一次。多西紫杉醇75mg/m2,每21d重复一次。按WHO疗效评价标准评价疗效,按WHO化疗药物急性和亚急性不良反应评价标准评价不良反应。结果全组16例患者术前共完成68次新辅助化疗(范围4～6次),所有患者均可评价疗效。16例患者中完全缓解4例,部分缓解10例,病情稳定2例,客观有效率(CR+PR)87.5%。全组均可评价不良反应,主要不良反应为骨髓抑制,其中Ⅲ～Ⅳ度白细胞减少发生率为62.5%,部分患者有轻度的心肌劳损。结论曲妥珠单抗联合多西紫杉醇对Her-2/neu高表达的局部晚期乳腺癌新辅助化疗的疗效较高,不良反应轻,患者可以耐受。
Objective To evaluate the efficacy of trastuzumab combined with docetaxel in the treatment of local late-stage breast cancer overexpressing Her-2 /neu before operation. Methods Sixteen patients with local late-stage breast cancer overexpressing Her-2 /neu were enrolled in the study. Trastuzumab was administrated on day 1 and repeated every 7 days. The initial dose of trastuzumab was 4mg/kg and subsequent doses were 2 mg/kg. Docetaxel（ 75mg/m2） was administrated on day 1 and repeated every 21 days. Results Overall 68 cycles were administrated to the 16 patients（ range 4-6 cycles/patient） . All cases were evalu-able. The overall response rate was 87. 5% （ 14 /16） . The major toxicity was myelosuppression. A few patients had fever at first infusion of trastuzumab and minor heart failure. Conclusions Trastuzumab combined with docetaxel is an effective and well-tolerated therapy for local late-stage breast cancer overexpressing Her-2 /neu.
出处
《中国肿瘤临床与康复》
2010年第5期433-435,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
